Intellia Therapeutics, Inc. (NTLA) income statement
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.77−0.01 (-0.10%)
Close on Nov 18, 2026Market cap $1.37BP/E –Yield –
Intellia Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -711.7%
- Net margin
- -672.2%
- Return on equity, FY2025
- -53.5%
Financial strength
- Current ratio
- 6.65
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 133.7%
Valuation
- P/E ratio
- –
- Price to sales
- 23.01
- Price to book
- 1.88
- Dividend yield
- –
See a number that looks wrong?